FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting.The designation recognizes the program ...
Telix Pharmaceuticals (ASX:TLX) has secured FDA Fast Track for its BiPASS program, opening the pre-biopsy prostate cancer ...
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging. Melbourne (Australia) and Indianapolis, IN (United States) \| September 30, 2026. FDA Fast T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results